Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The science behind Perspective Therapeutics’ Pb-212 alpha therapies is as advanced as its SEC disclosures are dense. Clinical trial readouts, isotope supply agreements and cash-runway forecasts are scattered across 300-page documents, leaving investors hunting for the numbers that matter. Whether you are searching for “Perspective Therapeutics insider trading Form 4 transactions” or trying to decode the latest “Perspective Therapeutics quarterly earnings report 10-Q filing,” the challenge is the same: translating technical oncology language into clear investment signals.
Stock Titan solves this problem by layering AI summaries, expert tagging and real-time EDGAR feeds onto every Perspective Therapeutics filing. Ask naturally—“understanding Perspective Therapeutics SEC documents with AI” or “Perspective Therapeutics 8-K material events explained”—and the platform surfaces concise answers. Our tools link each disclosure to its form type, so you can move from a “Perspective Therapeutics annual report 10-K simplified” overview to drill-downs on segment R&D spend, or jump straight to “Perspective Therapeutics Form 4 insider transactions real-time” for alerts when executives trade shares. Quarterly calls approaching? The “Perspective Therapeutics earnings report filing analysis” module highlights trial-cost trends before the market reacts.
Practical insight is our focus. Use insider dashboards to trace “Perspective Therapeutics executive stock transactions Form 4,” monitor dilution risk via shelf-registration statements, or check the “Perspective Therapeutics proxy statement executive compensation” section to evaluate incentive alignment with Pb-212 milestones. Every document—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, time-stamped and cross-linked, giving you comprehensive coverage without combing through technical appendices. Complex biotech filings, explained simply; real-time intelligence, delivered the moment it matters.
Perspective Therapeutics, Inc. is a radiopharmaceutical developer focused on targeted alpha therapies. At June 30, 2025 the company reported $28.85 million in cash and $162.73 million in short-term investments (combined $191.6 million), and management believes these resources will fund current planned operations into late 2026.
Operating spending rose notably year-over-year as R&D increased to $30.95 million for the six months ended June 30, 2025 and total operating expenses were $46.50 million, producing a six-month net loss of $39.66 million. The balance sheet shows total assets of $310.7 million, an accumulated deficit of $271.4 million and 74,262,990 common shares outstanding (per the filing).
Clinical progress reported: opening of Cohort 3 for [212Pb]VMT-α-NET (Cohort 2 had 46 patients treated), FDA "study may proceed" for PSV359 with two patients treated as of July 31, 2025, and Fast Track designation for [212Pb]VMT01. The company also reported recent patent grants and continued investments in manufacturing capacity.
Perspective Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and furnished that press release as Exhibit 99.1 to this Form 8-K. The filing also states the company posted an updated corporate presentation on its website and furnished that presentation as Exhibit 99.2. The 8-K clarifies that the information is "furnished" and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act.
The filing text does not include the actual financial figures or metrics; those details are contained in the referenced exhibits. This disclosure informs investors that quarter-end results and investor materials have been released, while the legal notice about furnishing limits incorporation and Section 18 liability.
Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.
Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.
The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
